Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Colin Baigent,Lisa Blackwell,Rory Collins,Jonathan Emberson,Jon Godwin,Richard Peto,Julie E. Buring,Charles H. Hennekens,Patricia M. Kearney,Tom W. Meade,Carlo Patrono,Maria Carla Roncaglioni,Alberto Zanchetti +12 more
Reads0
Chats0
TLDR
In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.About:
This article is published in The Lancet.The article was published on 2009-05-30 and is currently open access. It has received 2954 citations till now. The article focuses on the topics: Stroke & Aspirin.read more
Citations
More filters
Journal ArticleDOI
Aspirin for primary prevention of cardiovascular disease events.
Carrie W. Nemerovski,Francine D. Salinitri,Kathryn A. Morbitzer,Lynette R. Moser,Lynette R. Moser +4 more
TL;DR: Until more data are available, an individualized assessment of CVD risk with careful evaluation of risk and benefit should be performed before recommending aspirin therapy for primary prevention of CVC.
Journal ArticleDOI
Annual Risk of Major Bleeding Among Persons Without Cardiovascular Disease Not Receiving Antiplatelet Therapy
Vanessa Selak,Andrew Kerr,Andrew Kerr,Katrina Poppe,Billy Wu,Matire Harwood,Corina Grey,Rod Jackson,Sue Wells +8 more
TL;DR: In a population not receiving antiplatelet therapy, the annual risk of major bleeding events and nonfatal major bleeding was estimated and could inform population-level guidelines for primary prevention of CVD.
Journal ArticleDOI
Does modern medicine increase life-expectancy: Quest for the Moon Rabbit?
TL;DR: The search for elixir of immortality has yielded mixed results, the only strategies of proven benefit in primary/primordial prevention are pursuing a healthy life-style and its modification when appropriate, like cessation of smoking, weight reduction, increasing physical activity, eating a healthy diet and bringing blood pressure, serum cholesterol, and blood glucose under control.
Book ChapterDOI
Coxibs: Pharmacology, Toxicity and Efficacy in Cancer Clinical Trials
TL;DR: The clinical data and plausible mechanisms of CV hazards associated with traditional NSAIDs and coxibs are discussed, and the use of low-dose aspirin may have a place for chemoprevention of CRCs.
Journal ArticleDOI
2018 Guidelines of the Taiwan Society of Cardiology, Taiwan Society of Emergency Medicine and Taiwan Society of Cardiovascular Interventions for the management of non ST-segment elevation acute coronary syndrome
Yi-Heng Li,Yu-Chen Wang,Yi-Chih Wang,Ju-Chi Liu,Cheng Han Lee,Chun-Chi Chen,I-Chang Hsieh,Feng-You Kuo,Wei-Chun Huang,Shih-Hsien Sung,Chiung-Zuan Chiu,Jung-Cheng Hsu,Shu-Long Jen,Juey-Jen Hwang,Jiunn Lee Lin,Jiunn Lee Lin +15 more
TL;DR: For rapid diagnosis, 0/3 h rapid diagnosis protocol with high sensitivity cardiac troponin assay is recommended in this guideline, and the duration of dual antiplatelet therapy should be given for at least 12 months after discharge.
References
More filters
Journal ArticleDOI
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Colin Baigent,Anthony C Keech,Patricia M. Kearney,L Blackwell,Georgina Buck,Christine Pollicino,Adrienne Kirby,T Sourjina,Richard Peto,Rory Collins,R. J. Simes +10 more
TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Journal ArticleDOI
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson,Alberto Zanchetti,S. George Carruthers,Björn Dahlöf,Dag Elmfeldt,Stevo Julius,Joël Ménard,Karl Heinz Rahn,Hans Wedel,Sten Westerling +9 more
TL;DR: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Gary Whitlock,Sarah Lewington,Paul Sherliker,Robert Clarke,Jonathan Emberson,Jim Halsey,Nawab Qizilbash,Rory Collins,Richard Peto +8 more
TL;DR: Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer, despite cigarette consumption per smoker varying little with BMI.